← back to search

Emmanuelle Bompas

Hôpital Cochin · FR
Area of research
Pulmonary and Respiratory Medicine · Gastroenterology
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Gastrointestinal Tumor Research and Treatment, Cardiac tumors and thrombi, and Vascular Tumors and Angiosarcomas.
h-index
60
citations
13,178
works
347
NIH funding
primary concept
Medicine
email

Recent publications

Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group
European Journal of Cancer 2026cited by 0position: contributordoi
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial.
2025cited by 19position: contributordoi
Relative Dose Intensity of Trabectedin and Outcome of Advanced L-Sarcomas.
2025cited by 4position: contributordoi
Primary ovarian leiomyosarcoma: results from an analysis by the French Sarcoma Group (Ovarian SArcoma MAnagement - OSAMA Study).
2025cited by 1position: contributordoi
Improved nationwide survival of sarcoma patients with a network of reference centers
Annals of Oncology 2024cited by 45position: middledoi
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Annals of Oncology 2024cited by 33position: middledoi
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
The Lancet Oncology 2024cited by 22position: middledoi
Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma
ESMO Open 2024cited by 4position: contributordoi
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Journal of Clinical Oncology 2023cited by 313position: middledoi
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
The Lancet Oncology 2023cited by 83position: middledoi
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study.
2023cited by 22position: contributordoi
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
European Journal of Cancer 2023cited by 21position: middledoi
Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma group.
2023cited by 20position: contributordoi
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
2022cited by 228position: contributordoi
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
The Lancet Oncology 2022cited by 124position: middledoi
Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group.
2022cited by 8position: contributordoi
Shortening the Time Interval for the Referral of Patients With Soft Tissue Sarcoma to Expert Centers Using Mobile Health: Retrospective Study.
2022cited by 7position: contributordoi
Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group.
2022cited by 2position: contributordoi
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology 2021cited by 228position: middledoi
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
2021cited by 151position: contributordoi
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial
Annals of Oncology 2021cited by 48position: middledoi
High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.
Journal of Clinical Oncology 2021cited by 27position: middledoi
Determinants of the access to remote specialised services provided by national sarcoma reference centres
BMC Cancer 2021cited by 19position: middledoi
Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?
2021cited by 16position: contributordoi
Determinants of the access to remote specialised services provided by national sarcoma reference centres.
2021cited by 15position: contributordoi
Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network.
2021cited by 7position: contributordoi
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
2020cited by 601position: contributordoi
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
2020cited by 246position: contributordoi
Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study
Annals of Surgical Oncology 2020cited by 66position: middledoi
Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study.
2020cited by 38position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Jean‐Yves Blay · International Network for Economic, Social and Cultural Rights28 papers (2012–2026)Nicolas Penel · Université de Lille21 papers (2012–2024)Antoine Italiano · Centre de Recherche des Cordeliers16 papers (2019–2025)François Bertucci · Université de Bordeaux14 papers (2012–2024)Sophie Piperno‐Neumann · Université Paris Sciences et Lettres13 papers (2014–2022) · 12 papers (2019–2026)Antoîne Italiano · Institut Bergonié10 papers (2015–2024)Florence Duffaud · Aix-Marseille Université10 papers (2012–2026)François Bertucci · Université de Bordeaux9 papers (2019–2023) · 9 papers (2022–2026)Didier Cupissol · Institut de Recherche en Cancérologie de Montpellier8 papers (2014–2022)Nicolás Isambert · Université de Poitiers7 papers (2015–2022)Christine Chevreau · Institut Claudius Regaud7 papers (2014–2022)María Rios · Hospital César Milstein7 papers (2016–2024)Pascaline Boudou‐Rouquette · Assistance Publique – Hôpitaux de Paris7 papers (2017–2023)Olivier Mir · Amgen (United States)7 papers (2015–2021)Isabelle Ray‐Coquard · AbbVie (United States)6 papers (2014–2024)Esma Saâda-Bouzid · Centre Antoine Lacassagne6 papers (2015–2024)Axel Le Cesne · KU Leuven6 papers (2014–2024)Olivier Collard · Centre Jean Perrin6 papers (2014–2024)